ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2011
Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction.
Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 80 citations in OpenAlex.
- Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex.Transfusion · 2026Article
- Irradiation with 265-nm Ultraviolet Light-Emitting Diodes to Plasma: Alterations of Hemostatic Parameters and von Willebrand Factor.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Article
- aPDI meets PPE: photochemical decontamination in healthcare using methylene blue-where are we now, where will we go?Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Photodynamic Inactivation of Bovine Coronavirus with the Photosensitizer Toluidine Blue O.Viruses · 2023Article
- Interaction of Methylene Blue with Severe Acute Respiratory Syndrome Coronavirus 2 Envelope Revealed by Molecular Modeling.International journal of molecular sciences · 2023Article
- Near-Infrared Dyes: Towards Broad-Spectrum Antivirals.International journal of molecular sciences · 2022Review
- Anti-Viral Photodynamic Inactivation of T4-like Bacteriophage as a Mammalian Virus Model in Blood.International journal of molecular sciences · 2022Article
- Of masks and methylene blue-The use of methylene blue photochemical treatment to decontaminate surgical masks contaminated with a tenacious small nonenveloped norovirus.American journal of infection control · 2022Article
- Infectivity and Morphology of Bovine Coronavirus Inactivated In Vitro by Cationic Photosensitizers.Viruses · 2022Article
- Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.Blood transfusion = Trasfusione del sangue · 2022Article
- UVC disinfects SARS-CoV-2 by induction of viral genome damage without apparent effects on viral morphology and proteins.Scientific reports · 2021Article
- Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020Review
- Article
- Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.Blood transfusion = Trasfusione del sangue · 2019Article
- Article
- Light-based methods for whole blood bacterial inactivation enabled by a recirculating flow system.Photochemistry and photobiology · 2018Article
- Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.Blood transfusion = Trasfusione del sangue · 2018Article
- Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.Blood transfusion = Trasfusione del sangue · 2016Review
- Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.Transfusion medicine reviews · 2016Article
- A New Proof of Concept in Bacterial Reduction: Antimicrobial Action of Violet-Blue Light (405 nm) inJournal of blood transfusion · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylene blue (MB) treated plasma has been in clinical use for 18 years. The current THERAFLEX MB-Plasma has a number of improved features compared with the original Springe methodology. This overview embodies: the biochemical characteristics of MB, the mechanism of the technology, toxicology, pathogen reduction capacity, current position in clinical setting and status within Europe. The THERAFLEX MB (TMB) procedure is a robust, well standardised system lending itself to transfusion setting and meets the current guidelines. The pathogen kill power of the TMB system, like the other available technologies, is not limitless, probably in order of 6 log for most enveloped viruses and considerably less for non-enveloped ones. It does not induce either new antigen or grossly reducing the function and life span of active principle in fresh frozen plasma (FFP). The removal of the residual MB at the end of the process has the beneficial effect of reducing potential toxic impacts. Clinical haemovigilance data, so far, indicate that cell-free MB plasma is effective in all therapeutic setting requiring FFP, besides inconsistent thrombotic thrombocytopenia purpura data, without serious side-effects or toxicity. The current system is in continuous improvement e.g. regarding virus reduction range, illumination device, software used, and process integration in the blood bank setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.